home / stock / pdsb / pdsb news

PDSB News and Press, PDS Biotechnology Corporation From 05/25/22

Stock Information
Company Name: PDS Biotechnology Corporation
Stock Symbol: PDSB
Market: NASDAQ
Website: pdsbiotech.com
Menu
PDSB PDSB Quote PDSB Short PDSB News PDSB Articles PDSB Message Board
Get PDSB Alerts

News, Short Squeeze, Breakout and More Instantly...
PDSB - PDS Biotechnology to Host Conference Call Following Poster Presentations of PDS0101 Data at 2022 ASCO Annual Meeting

FLORHAM PARK, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines, today announced its management team will ho...
PDSB - PDS Biotechnology Appoints Seasoned Business Development Executive Sanjay Zaveri as Senior Vice President, Business Development

FLORHAM PARK, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Ve...

PDSB - PDS Biotech to Participate at Upcoming Investor Conferences

FLORHAM PARK, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Ve...

PDSB - PDS Biotechnology Corp (PDSB) - Clinical Progress Continues As 1Q22 Results Were Within Expectations

PDS Biotechnology Reported 1Q22. PDS Biotechnology reported a loss of $8.5 million or $(0.32) per share for 1Q22, consistent with our expectations. The company also gave updates on its clinical trials and pipeline products, and has two upcoming poster presentations scheduled to provide clinica...
PDSB - PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q1 2022 Results - Earnings Call Transcript

PDS Biotechnology Corporation. (PDSB) Q1 2022 Earnings Conference Call May 11, 2022, 08:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Officer Confe...

PDSB - PDS Biotechnology GAAP EPS of -$0.32 misses by $0.09

PDS Biotechnology press release (NASDAQ:PDSB): Q1 GAAP EPS of -$0.32 misses by $0.09. Cash and cash equivalents of $58.9M For further details see: PDS Biotechnology GAAP EPS of -$0.32 misses by $0.09

PDSB - PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results

FLORHAM PARK, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s propri...
PDSB - PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2022 Financial Results

FLORHAM PARK, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing molecularly targeted cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Inf...

PDSB - PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

Preliminary efficacy and safety update on PDS0101 in combination with KEYTRUDA ® (pembrolizumab) in first-line recurrent or metastatic HPV-positive head and neck cancer Preliminary efficacy and safety update by NCI on PDS0101-based triple combination in advanced...

PDSB - PDS Biotech Chief Medical Officer, Lauren V. Wood, to Chair Session at the World Vaccine Congress

FLORHAM PARK, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary ...
Previous 10 Next 10